S&P 500   4,330.00
DOW   34,070.42
QQQ   357.86
3 Reasons this Tech Giant is Going Back to Highs
66,000% upside on tiny biotech? (Ad)
3 Compelling Reasons to Start Buying Undervalued Amazon
5 Reasons Why Amprius is About to Take Flight 
66,000% upside on tiny biotech? (Ad)
Stock market today: World shares are mixed, Chinese markets surge, after latest retreat on Wall St
Analysts Recommend These Mining Stocks Before Metal Prices Rally
66,000% upside on tiny biotech? (Ad)
5 Sizzling Tech Companies on the Brink of Bullish Reversals
FedEx, Greenbrier rise; Cisco Systems, KB Home fall, Thursday, 9/21/2023
S&P 500   4,330.00
DOW   34,070.42
QQQ   357.86
3 Reasons this Tech Giant is Going Back to Highs
66,000% upside on tiny biotech? (Ad)
3 Compelling Reasons to Start Buying Undervalued Amazon
5 Reasons Why Amprius is About to Take Flight 
66,000% upside on tiny biotech? (Ad)
Stock market today: World shares are mixed, Chinese markets surge, after latest retreat on Wall St
Analysts Recommend These Mining Stocks Before Metal Prices Rally
66,000% upside on tiny biotech? (Ad)
5 Sizzling Tech Companies on the Brink of Bullish Reversals
FedEx, Greenbrier rise; Cisco Systems, KB Home fall, Thursday, 9/21/2023
S&P 500   4,330.00
DOW   34,070.42
QQQ   357.86
3 Reasons this Tech Giant is Going Back to Highs
66,000% upside on tiny biotech? (Ad)
3 Compelling Reasons to Start Buying Undervalued Amazon
5 Reasons Why Amprius is About to Take Flight 
66,000% upside on tiny biotech? (Ad)
Stock market today: World shares are mixed, Chinese markets surge, after latest retreat on Wall St
Analysts Recommend These Mining Stocks Before Metal Prices Rally
66,000% upside on tiny biotech? (Ad)
5 Sizzling Tech Companies on the Brink of Bullish Reversals
FedEx, Greenbrier rise; Cisco Systems, KB Home fall, Thursday, 9/21/2023
S&P 500   4,330.00
DOW   34,070.42
QQQ   357.86
3 Reasons this Tech Giant is Going Back to Highs
66,000% upside on tiny biotech? (Ad)
3 Compelling Reasons to Start Buying Undervalued Amazon
5 Reasons Why Amprius is About to Take Flight 
66,000% upside on tiny biotech? (Ad)
Stock market today: World shares are mixed, Chinese markets surge, after latest retreat on Wall St
Analysts Recommend These Mining Stocks Before Metal Prices Rally
66,000% upside on tiny biotech? (Ad)
5 Sizzling Tech Companies on the Brink of Bullish Reversals
FedEx, Greenbrier rise; Cisco Systems, KB Home fall, Thursday, 9/21/2023
NASDAQ:ACCD

Accolade (ACCD) Stock Forecast, Price & News

$10.90
-0.82 (-7.00%)
(As of 09/21/2023 ET)
Compare
Today's Range
$10.85
$11.55
50-Day Range
$10.90
$15.02
52-Week Range
$6.83
$17.00
Volume
695,132 shs
Average Volume
624,960 shs
Market Capitalization
$824.37 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.59

Accolade MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
43.1% Upside
$15.59 Price Target
Short Interest
Healthy
4.42% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.85
Upright™ Environmental Score
News Sentiment
0.27mentions of Accolade in the last 14 days
Based on 8 Articles This Week
Insider Trading
Selling Shares
$103,506 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.72) to ($1.54) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.69 out of 5 stars

Business Services Sector

60th out of 312 stocks

Business Services, Not Elsewhere Classified Industry

20th out of 86 stocks


ACCD stock logo

About Accolade (NASDAQ:ACCD) Stock

Accolade, Inc., together with its subsidiaries, engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based technology and multimodal support from a team of health assistants and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women's health specialists, case management specialists, expert medical opinion providers, and virtual primary care physicians. It also provides medical opinion and decision support services; and technology and administrative services to the medical practice PCs providing virtual primary care services. The company serves employers who provide their employees and their employees' families a single place to turn for their health, healthcare, and benefits needs. Accolade, Inc. was incorporated in 2007 and is headquartered in Seattle, Washington.

ACCD Price History

ACCD Stock News Headlines

BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
Accolade (NASDAQ: ACCD)
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
Accolade To Present at Upcoming Investor Conferences
The Latest Analyst Ratings for Accolade
Truist Financial Sticks to Its Buy Rating for Accolade (ACCD)
Why Accolade Stock Popped by Almost 7% Today
SVB Securities Reaffirms Their Hold Rating on Accolade (ACCD)
Accolade Rises as Losses Narrow in Q1
See More Headlines
Receive ACCD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Accolade and its competitors with MarketBeat's FREE daily newsletter.

ACCD Company Calendar

Last Earnings
6/29/2023
Today
9/21/2023
Next Earnings (Confirmed)
10/04/2023
Fiscal Year End
2/29/2024

Industry, Sector and Symbol

Industry
Business services, not elsewhere classified
Sub-Industry
N/A
Current Symbol
NASDAQ:ACCD
Fax
N/A
Employees
2,370
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$15.59
High Stock Price Forecast
$19.00
Low Stock Price Forecast
$13.00
Forecasted Upside/Downside
+43.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
15 Analysts

Profitability

Net Income
$-459,650,000.00
Pretax Margin
-41.76%

Debt

Sales & Book Value

Annual Sales
$363.14 million
Book Value
$6.51 per share

Miscellaneous

Free Float
69,354,000
Market Cap
$824.37 million
Optionable
Not Optionable
Beta
1.74
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Mr. Rajeev Singh (Age 55)
    Chairman & CEO
    Comp: $778.5k
  • Mr. Robert Cavanaugh (Age 54)
    Pres
    Comp: $582.63k
  • Mr. Stephen H. Barnes CPA (Age 51)
    CFO & Treasurer
    Comp: $557.5k
  • Ms. Kristen Bruzek
    Sr. VP of Operations
  • Mr. Colin McHugh (Age 44)
    Chief Accounting Officer
  • Mr. Todd Friedman
    Sr. VP of Investor Relations
  • Mr. Richard Eskew (Age 48)
    Exec. VP, Gen. Counsel, CCO & Sec.
  • Ms. Jennifer Hanson
    Exec. VP & Chief Human Resource Officer
  • Mr. Drew Garner
    Exec. VP of Engineering
  • Dr. Shantanu Nundy M.B.A.
    M.D., Exec. VP of Care Delivery, Chief Health Officer & Member of the Medical Advisory Board













ACCD Stock - Frequently Asked Questions

Should I buy or sell Accolade stock right now?

15 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Accolade in the last twelve months. There are currently 5 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ACCD shares.
View ACCD analyst ratings
or view top-rated stocks.

What is Accolade's stock price forecast for 2023?

15 analysts have issued twelve-month target prices for Accolade's shares. Their ACCD share price forecasts range from $13.00 to $19.00. On average, they anticipate the company's stock price to reach $15.59 in the next year. This suggests a possible upside of 43.1% from the stock's current price.
View analysts price targets for ACCD
or view top-rated stocks among Wall Street analysts.

How have ACCD shares performed in 2023?

Accolade's stock was trading at $7.79 at the start of the year. Since then, ACCD shares have increased by 39.9% and is now trading at $10.90.
View the best growth stocks for 2023 here
.

When is Accolade's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, October 4th 2023.
View our ACCD earnings forecast
.

How were Accolade's earnings last quarter?

Accolade, Inc. (NASDAQ:ACCD) released its quarterly earnings data on Thursday, June, 29th. The company reported ($0.52) earnings per share for the quarter, topping analysts' consensus estimates of ($0.62) by $0.10. The business had revenue of $93.20 million for the quarter, compared to analyst estimates of $90.82 million. Accolade had a negative net margin of 41.86% and a negative trailing twelve-month return on equity of 32.34%. The company's quarterly revenue was up 9.0% compared to the same quarter last year. During the same period last year, the business earned ($0.62) EPS.

What guidance has Accolade issued on next quarter's earnings?

Accolade updated its second quarter earnings guidance on Wednesday, July, 12th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $93.00 million-$95.00 million, compared to the consensus revenue estimate of $93.22 million.

What is Rajeev Singh's approval rating as Accolade's CEO?

152 employees have rated Accolade Chief Executive Officer Rajeev Singh on Glassdoor.com. Rajeev Singh has an approval rating of 74% among the company's employees.

What other stocks do shareholders of Accolade own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Accolade investors own include CVS Health (CVS), Johnson & Johnson (JNJ), RTX (RTX), Alibaba Group (BABA), Home Depot (HD), Procter & Gamble (PG), Thermo Fisher Scientific (TMO), Cisco Systems (CSCO) and Intel (INTC).

When did Accolade IPO?

(ACCD) raised $176 million in an IPO on Thursday, July 2nd 2020. The company issued 8,800,000 shares at a price of $19.00-$21.00 per share. Goldman Sachs, Morgan Stanley and BofA Securities acted as the underwriters for the IPO and Piper Sandler, Credit Suisse, William Blair, Baird and SVB Leerink were co-managers.

What is Accolade's stock symbol?

Accolade trades on the NASDAQ under the ticker symbol "ACCD."

Who are Accolade's major shareholders?

Accolade's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include JPMorgan Chase & Co. (8.72%), Brown Advisory Inc. (8.06%), ARK Investment Management LLC (7.52%), Bellevue Group AG (5.98%), Rock Springs Capital Management LP (3.73%) and Dimensional Fund Advisors LP (2.05%). Insiders that own company stock include Colin Mchugh, Michael W Hilton, Rajeev Singh, Richard Eskew, Robert N Cavanaugh, Stephen H Barnes and Thomas J Neff.
View institutional ownership trends
.

How do I buy shares of Accolade?

Shares of ACCD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Accolade's stock price today?

One share of ACCD stock can currently be purchased for approximately $10.90.

How much money does Accolade make?

Accolade (NASDAQ:ACCD) has a market capitalization of $824.37 million and generates $363.14 million in revenue each year. The company earns $-459,650,000.00 in net income (profit) each year or ($2.16) on an earnings per share basis.

How many employees does Accolade have?

The company employs 2,370 workers across the globe.

How can I contact Accolade?

Accolade's mailing address is 660 W. GERMANTOWN PIKE SUITE 500, PLYMOUTH MEETING PA, 19462. The official website for the company is accolade.com. The company can be reached via phone at 206-926-8100 or via email at ir@accolade.com.

This page (NASDAQ:ACCD) was last updated on 9/22/2023 by MarketBeat.com Staff

My Account -